Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.

eqs_en 
0 0 19.03.24
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
 

EQS-Ad-hoc: Eckert Ziegler SE / Key word(s): Dividend
Eckert Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.

19-March-2024 / 19:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 19 March 2024 – The Supervisory Board and Executive Board of Eckert Ziegler (ISIN DE0005659700, TecDAX) today decided to propose to the Annual General Meeting a reduced dividend of € 0.05 per share entitled to a dividend. The liquidity thus remaining in the company will be used to finance new high-return projects in the continuously growing market for radiopharmaceuticals. This includes, in particular, the expansion of global production capacities. The dividend reduction is also intended to ensure greater independence from external financing.

In addition to the reduced dividend, EZAG shareholders are to receive one additional Pentixapharm share for each EZAG share in the course of the planned split-off of Pentixapharm AG.

In the 2023 financial year, the Eckert Ziegler Group increased sales by 11% to € 246.1 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.

For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT from continuing operations before one-off effects of around € 50 million.

The detailed annual financial statements for 2023 will be published on March 22, 2024.

For enquiries please contact:
Eckert Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com 



End of Inside Information

19-March-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Eckert Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1862489

 
End of Announcement EQS News Service

1862489  19-March-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1862489&application_name=news&site_id=sharewise~~~202ee175-2c72-4a50-a0f7-89cd8fcfa533

Eckert & Ziegler Strahlen- und Medizintechnik AG Stock

€39.98
-0.100%

Eckert & Ziegler Strahlen- und Medizintechnik AG is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 39.98 € the target price of 95 € shows a potential of 137.62% for Eckert & Ziegler Strahlen- und Medizintechnik AG which would more than double the current price.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!